Castleman disease - null regimens
Jump to navigation
Jump to search
The purpose of this page is to provide references to "null therapy" such as placebo and observation. These references provide further insight into the historical development of the treatment landscape. See the main Castleman disease page for regimens that include active anticancer treatment.
HHV-8-negative/"Idiopathic" multicentric Castleman disease, all lines of therapy
Placebo
Regimen
| Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|---|
| van Rhee et al. 2014 (CR016705) | 2010-02-09 to 2012-02-03 | Randomized Phase 2 (C) | Siltuximab | Inferior durable tumor and symptomatic response for at least 18 weeks |
No active treatment; all patients did receive "best supportive care."
References
- CR016705: van Rhee F, Wong RS, Munshi N, Rossi JF, Ke XY, Fosså A, Simpson D, Capra M, Liu T, Hsieh RK, Goh YT, Zhu J, Cho SG, Ren H, Cavet J, Bandekar R, Rothman M, Puchalski TA, Reddy M, van de Velde H, Vermeulen J, Casper C. Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2014 Aug;15(9):966-74. Epub 2014 Jul 17. Erratum in: Lancet Oncol. 2014 Sep;15(10):417. link to original article PubMed NCT01024036